» Articles » PMID: 20008785

A Dynamic Prognostic Model to Predict Survival in Primary Myelofibrosis: a Study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

Abstract

Age older than 65 years, hemoglobin level lower than 100 g/L (10 g/dL), white blood cell count greater than 25 x 10(9)/L, peripheral blood blasts 1% or higher, and constitutional symptoms have been shown to predict poor survival in primary myelofibrosis (PMF) at diagnosis. To investigate whether the acquisition of these factors during follow-up predicts survival, we studied 525 PMF patients regularly followed. All 5 variables had a significant impact on survival when analyzed as time-dependent covariates in a multivariate Cox proportional hazard model and were included in 2 separate models, 1 for all patients (Dynamic International Prognostic Scoring System [DIPSS]) and 1 for patients younger than 65 years (age-adjusted DIPSS). Risk factors were assigned score values based on hazard ratios (HRs). Risk categories were low, intermediate-1, intermediate-2, and high in both models. Survival was estimated by the HR. When shifting to the next risk category, the HR was 4.13 for low risk, 4.61 for intermediate-1, and 2.54 for intermediate-2 according to DIPSS; 3.97 for low risk, 2.84 for intermediate-1, and 1.81 for intermediate-2 according to the age-adjusted DIPSS. The novelty of these models is the prognostic assessment of patients with PMF anytime during their clinical course, which may be useful for treatment decision-making.

Citing Articles

Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment - an intraindividual analysis by the German Study Group for MPN (GSG-MPN).

Manz K, Heidel F, Koschmieder S, Schlag R, Lipke J, Stegelmann F Leukemia. 2025; .

PMID: 40000843 DOI: 10.1038/s41375-025-02524-7.


Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real-world ERNEST-2 registry.

Guglielmelli P, Ghirardi A, Carobbio A, Masciulli A, Morrone L, Mora B Hemasphere. 2025; 9(2):e70072.

PMID: 39897086 PMC: 11783225. DOI: 10.1002/hem3.70072.


Reconstructing skeletal homeostasis through allogeneic hematopoietic stem cell transplantation in myelofibrosis.

Schaferskupper M, Simon A, Yorgan T, von Brackel F, Delsmann M, Baranowsky A Nat Commun. 2025; 16(1):741.

PMID: 39833182 PMC: 11747566. DOI: 10.1038/s41467-025-55915-w.


Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy.

Palandri F, Branzanti F, Morsia E, Dedola A, Benevolo G, Tiribelli M Ann Hematol. 2025; 104(1):241-251.

PMID: 39831987 PMC: 11868333. DOI: 10.1007/s00277-025-06204-5.


Red Blood Cell Distribution Width May Predict Drug-Induced Anemia and Prognosis in Patients Affected by Primary/Secondary Myelofibrosis Treated with Ruxolitinib.

Lagana A, Scalzulli E, Carmosino I, Bisegna M, Martelli M, Breccia M Oncol Ther. 2025; 13(1):165-183.

PMID: 39821749 PMC: 11880497. DOI: 10.1007/s40487-024-00322-2.